• Explore /
  • Poster
  • / Whole blood androgen receptor (AR) variant (ARV12, ARV14) expression and overall survival (OS) in metastatic castrate resistant prostate cancer (mCRPC).

Whole blood androgen receptor (AR) variant (ARV12, ARV14) expression and overall survival (OS) in metastatic castrate resistant prostate cancer (mCRPC).

Abstract Poster

Authors

null

Karthik Giridhar

Mayo Clinic, Rochester, MN

Karthik Giridhar , Carlos Sosa , David W. Hillman , Cristobal T. Sanhueza , Liguo Wang , John C. Cheville , Scott Dehm , Manish Kohli

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary (Prostate) Cancer

Track

Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track

Epidemiology/Outcomes

Clinical Trial Registration Number

NCT#01953640

Citation

J Clin Oncol 35, 2017 (suppl; abstr 5058)

DOI

10.1200/JCO.2017.35.15_suppl.5058

Abstract #

5058

Poster Bd #

132

Abstract Disclosures

Similar Posters

First Author: Siyuan S Guo

First Author: Alexander Shiang

First Author: Justin Shaya

First Author: Christopher Sweeney